BERLIN, March 7 /PRNewswire-FirstCall/ -- Schering AG, Germany announced today that its Supervisory Board will, on the occasion of its Annual General Meeting on April 19, 2006, recommend the election of Professor Dr. Dieter Hinzen (66) as a new member of the Supervisory Board representing the shareholders. If confirmed, Professor Hinzen would succeed Professor Dr. Piet Borst, who will retire from the Supervisory Board with the end of the Annual General Meeting.
"Professor Hinzen combines experience in the pharmaceutical industry along with scientific know-how in research and development. This will further complement the expertise of Schering's Supervisory Board," said Dr. Giuseppe Vita, Chairman of the Supervisory Board of Schering AG.
"The future growth of the pharmaceutical industry depends on its capability to create innovative medicines and diagnostic tools. I am therefore excited about the opportunity to work with a research-based company of Schering's global position and caliber. The products, strategic goals, and prospects of Schering meet high expectations. It would be my goal to contribute to Schering's worldwide reputation and success," said Professor Hinzen.
Professor Hinzen holds a doctorate in medicine from the University of Cologne, Germany, and habilitated in Physiology. After working as a professor at the "Centre National de la Recherche Scientifique", Gif-sur-Yvette, France, Hinzen held several key positions in the pharmaceutical industry. He worked for F. Hoffmann-La Roche, Switzerland, and Boehringer Ingelheim, Germany, for over twenty years with managing responsibilities in research and development.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology & Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work
This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.
Additional information at: www.schering.de/eng
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Your contacts at Corporate Communication:
Media Relations: Oliver Renner, T: +49-30-468-124-31, oliver.renner@schering.de
Media Relations: Verena von Bassewitz, T: +49-30-468-19-22-06, verena.vonbassewitz@schering.de
Investor Relations: Peter Vogt, T: +49-30-468-128-38, peter.vogt@schering.de
Schering AGCONTACT: Media Relations: Oliver Renner, T: +49-30-468-124-31,oliver.renner@schering.de. Media Relations: Verena von Bassewitz, T:+49-30-468-19-22-06, verena.vonbassewitz@schering.de. Investor Relations:Peter Vogt, T: +49-30-468-128-38, peter.vogt@schering.de
